Back to Interventions
Substance / Medication

Clidinium bromide

SNOMED 87283008UMLS C0110059

Overview

Clinical overview including description, indications, and evidence base is pending physician authorship or FDA SPL integration. Graph-derived relationship data is available below.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Peptic ulcer
Inflammatory bowel disease

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Erythrocyte

LOINC 4537-7

secondary

C reactive protein

LOINC 1988-5

primary

Neutrophils

LOINC 770-8

primary

Research Evidence

Published studies and systematic reviews

Sort:
Combined aclidinium bromide and long-acting beta2-agonist for chronic obstructive pulmonary disease (COPD).
Ni Han, Moe Soe, Soe Zay et al. · Cochrane Database Syst Rev · 2018
PMID: 30536566Meta-AnalysisFull text (PMC)
Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD).
Ni Han, Htet Aung, Moe Soe · Cochrane Database Syst Rev · 2017
PMID: 28631387Meta-AnalysisFull text (PMC)
Efficacy and Safety of an Aclidinium Bromide Treatment for 12 Weeks or Longer in Patients with Moderate-To-Severe COPD: A Meta-Analysis.
Zou Yong, Xiao Jian, Yang Dan Hui et al. · COPD · 2016
PMID: 26846588Meta-Analysis
Aclidinium bromide for stable chronic obstructive pulmonary disease.
Ni Han, Soe Zay, Moe Soe · Cochrane Database Syst Rev · 2014
PMID: 25234126Meta-AnalysisFull text (PMC)
ACCORD COPD II: a randomized clinical trial to evaluate the 12-week efficacy and safety of twice-daily aclidinium bromide in chronic obstructive pulmonary disease patients.
Rennard Stephen I, Scanlon Paul D, Ferguson Gary T et al. · Clin Drug Investig · 2013
PMID: 24085591RCT
Efficacy of aclidinium bromide 400 μg twice daily compared with placebo and tiotropium in patients with moderate to severe COPD.
Fuhr Rainard, Magnussen Helgo, Sarem Kristina et al. · Chest · 2012
PMID: 21903737RCT
Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the ATTAIN study.
Jones Paul W, Singh Dave, Bateman Eric D et al. · Eur Respir J · 2012
PMID: 22441743RCT
Real-world effectiveness of single-inhaler fluticasone furoate/umeclidinium bromide/vilanterol in Chinese patients with symptomatic chronic obstructive pulmonary disease (COPD): a post-marketing, prospective, multicenter, observational study.
Ma Jinfang, Dou Fangfang, Zhou Wutie et al. · Curr Med Res Opin · 2025
PMID: 40704458Observational
A Real-World Observational Study Examining the Impact of Aclidinium Bromide Therapy on the Quality of Life, Symptoms, and Activity Impairment of Patients with Chronic Obstructive Pulmonary Disease: The Greek ON-AIR Study.
Kostikas Konstantinos, Vassilakopoulos Theodoros I, Tzanakis Nikos et al. · Int J Chron Obstruct Pulmon Dis · 2020
PMID: 32184588ObservationalFull text (PMC)
A comparison of the efficacy and safety of combined aclidinium bromide and formoterol fumarate in the treatment of chronic obstructive pulmonary disease: A protocol for systematic review and meta-analysis.
Lu Hong, Huang Yi-Tong, Chen He-Jiang et al. · Medicine (Baltimore) · 2020
PMID: 33217787ObservationalFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Specialists

Providers who commonly manage this intervention

Internal Medicine Physician

Internal Medicine

NUCC 207R00000X
Gastroenterology Physician

Internal Medicine — Gastroenterology

NUCC 207RG0100X
Find a Provider

Health Goals

Goals connected through associated conditions

Improve Gut Health

Quick Facts

Type
Substance / Medication
Fully Specified Name
Clidinium bromide (substance)
SNOMED CT
87283008
UMLS CUI
C0110059

Clinical Data

This intervention maps to 8 entities in the Ltrl knowledge graph.

2
Conditions
3
Biomarkers
2
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.